Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment
Journal of Affective Disorders · 2026-01 · 392 · 120192
DOI: 10.1016/j.jad.2025.120192 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Affective Disorders, 2026-01. Verfasst von Clara Massaneda-Tuneu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia; Ramsay Clinic Northside, S…. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Antidepressive Agents, Ketamine, Drugs, Generic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ramsay Hospital Research Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
Ketamine is a highly effective treatment for difficult-to-treat or treatment-resistant depression (TRD). The commercially developed intranasal spray containing S-ketamine has demonstrated short and long-term efficacy and safety in phase 3 clinical trials leading to regulatory approval for TRD in many countries. Conversely, generic racemic ketamine is prescribed 'off-label'. There is minimal data on the effectiveness and safety of generic racemic ketamine treatment of >4 weeks duration. The aim of this study was to report the effectiveness and safety of ongoing racemic ketamine treatment for TRD for up to six months in real-world clinical settings. Safety was assessed using a structured monitoring framework (Ketamine Side Effect Tool). Retrospective, deidentified data were collected and analysed from 65 patients with TRD (46.1 ± 14.9 years old; 52.3 % female) who received racemic ketamine treatments over a period of 8 weeks to 6 months. Effectiveness and safety data were summarised using descriptive statistics and frequency distributions. Data suggested effectiveness, with response rates of 35 % at 8 weeks (16/45) and 44.2 % at 6 months (19/43). Suicidality scores improved in 73.3 % of patients at their last available assessment. Similarly, the results indicated that racemic ketamine was well tolerated. Our findings suggest structured safety monitoring facilitated early identification of emerging adverse effects in a few patients, allowing prompt clinical management, with no adverse sequelae. These findings support the effectiveness and safety of long-term racemic ketamine treatment for patients with TRD and highlight the importance of using a structured safety monitoring framework in clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia; Ramsay Clinic Northside, St Leonards, Sydney, Australia. Electronic address: c.massaneda_tuneu@u…
- Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia; Ramsay Clinic Northside, St Leonards, Sydney, Australia; Black Dog Institute, Sydney, Australia;…
- Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Australia; ARC Centre of Excellence for Children and Families over the Life Course, Sydney, Australia.
- Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia.
- Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia; Black Dog Institute, Sydney, Australia.
- Black Dog Institute, Sydney, Australia.
Förderung
- Ramsay Hospital Research Foundation
- National Health and Medical Research Council
Zitieren
APA
Massaneda-Tuneu, C., Martin, D., Glozier, N., Bayes, A., Cao, T. V., Thornton, N., Brettell, L., Antoniou, S., Barreiros, A. R., Flynn, M., Dong, V., Lun, E., Karunaratne, N., Moreno, D., Ellis, J., Samuels, O., Fowler, I., Bull, M., Mitchell, P. B., & Loo, C. K. (2026). Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment. Journal of Affective Disorders, 392, 120192. https://doi.org/10.1016/j.jad.2025.120192
Vancouver
Massaneda-Tuneu C, Martin D, Glozier N, Bayes A, Cao TV, Thornton N, et al. Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment. Journal of Affective Disorders. 2026;392:120192. doi:10.1016/j.jad.2025.120192
BibTeX
@article{MassanedaTuneu2026,
author = {Massaneda-Tuneu, Clara and Martin, Donel and Glozier, Nicholas and Bayes, Adam and Cao, Thanh Vinh and Thornton, Nicollette and Brettell, Louise and Antoniou, Stella and Barreiros, Ana Rita and Flynn, Michaela and Dong, Vanessa and Lun, Elizabeth and Karunaratne, Natasha and Moreno, Dalia and Ellis, Justine and Samuels, Owen and Fowler, Ian and Bull, Michael and Mitchell, Philip B and Loo, Colleen K},
title = {Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {392},
pages = {120192},
doi = {10.1016/j.jad.2025.120192}
}
EUVIMED